More recently, it was suggested that CD36 is involved in SREBP1 processing and the lipogenic program in the liver by interacting with the insulin-induced gene 2 (INSIG2) and that hepatocyte CD36-mediated de novo lipogenesis is a critical factor in the development of NAFLD [63]. This evidence concerns the gene INSIG2 and metabolic dysfunction-associated steatotic liver disease.